Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04396340 · ClinicalTrials.gov registry record · Phase 1
First-in-Human Study of XMT-1592 in Patients With Ovarian Cancer and NSCLC Likely to Express NaPi2b
A Phase 1 study, sponsored by Mersana Therapeutics.
- Terminated
- Registry status
- Phase 1
- Development phase
- 31
- Enrollment target
NCT04396340 is a Phase 1 study that was terminated before completion, run by Mersana Therapeutics. The registered enrollment target is 31 participants.
The verdict
NCT04396340, a Phase 1 study, was terminated before completion, sponsored by Mersana Therapeutics.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 31 participants
- Enrollment target
Study Summary
Phase 1b, a study in high grade serous ovarian cancer and nonsmall cell lung cancer to evaluate the safety and clinical activity of the antibody-drug conjugate (ADC) XMT-1592.
Interventions
- BIOLOGICAL XMT-1592
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 31 participants |
| Start Date | 2020-05-11 |
| Est. Completion | 2022-09-30 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04396340
The ClinicalTrials.gov registry entry for NCT04396340 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 31 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Mersana Therapeutics, which has 11 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which XMT-1592 is the first listed.
NCT04396340 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04396340 about?
NCT04396340 is a clinical study titled "First-in-Human Study of XMT-1592 in Patients With Ovarian Cancer and NSCLC Likely to Express NaPi2b". Phase 1b, a study in high grade serous ovarian cancer and nonsmall cell lung cancer to evaluate the safety and clinical activity of the antibody-drug conjugate (ADC) XMT-1592.
What is the current status of trial NCT04396340?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 31 participants. The study started on 2020-05-11. Estimated completion is 2022-09-30.
What interventions are being tested in trial NCT04396340?
The interventions under investigation include: XMT-1592 (BIOLOGICAL).
Who is sponsoring clinical trial NCT04396340?
This trial is sponsored by Mersana Therapeutics, which has 11 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.